Accounts Receivable, after Allowance for Credit Loss, Current in USD of Humacyte, Inc. from Q4 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Humacyte, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q4 2020 to Q3 2025.
  • Humacyte, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2025 was $1.08M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Humacyte, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $1.08M Sep 30, 2025 10-Q 2025-11-12
Q2 2025 $394K Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $488K Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $180K +$180K Dec 31, 2024 10-Q 2025-11-12
Q4 2023 $0 -$31K -100% Dec 31, 2023 10-K 2024-03-28
Q3 2023 $0 -$31K -100% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $0 -$1.3M -100% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $0 -$233K -100% Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $31K -$145K -82.4% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $31K -$209K -87.1% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $1.3M Jun 30, 2022 10-Q 2022-08-12
Q1 2022 $233K Mar 31, 2022 10-Q 2022-05-13
Q4 2021 $176K +$63K +55.8% Dec 31, 2021 10-K 2023-03-24
Q3 2021 $240K Sep 30, 2021 10-Q 2021-11-15
Q4 2020 $113K Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.